Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATEV vs AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
NCT05908084Phase 3Active, not recruiting
- Sponsor
- Humacyte
- Start
- Sep 2023
- Primary completion
- Jun 2027
- Modality
- Device-based Delivery, Tissue Cells, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of acellular tissue engineered vessel in end stage renal disease (ESRD), sponsored by Humacyte. Started Sep 2023; status: active, not recruiting.
02
Drugs
acellular tissue engineered vessel
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT05908084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908084.